• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Zeiss broadens portfolio of IOLs

Article

Carl Zeiss Meditec AG has acquired-through its subsidiary Carl Zeiss Meditic Inc.-100% of the shares in Aaren Scientific Inc., a US-based manufacturer of IOLs.

 

Jena, Germany and Ontario, CA-Carl Zeiss Meditec AG has acquired-through its subsidiary Carl Zeiss Meditic Inc.-100% of the shares in Aaren Scientific Inc., a US-based manufacturer of IOLs.

The majority of shares in Aaren Scientific had previously been owned by a private investment company, as well as other investors, including the chief executive officer and co-founding of the company, Rick Aguilera.

Aguilera, along with Aaren Scientific’s entire management team, will stay on board after the transaction.

“The two companies, Zeiss and Aaren Scientific, are highly complementary and enable Zeiss to offer ophthalmic surgeons a broader portfolio of solutions,” said Ludwin Monz, PhD, executive board member, president, and chief executive officer of Zeiss Meditec AG. “By giving our customers a wider range of IOL choices than any other company, we will be in a position to provide them with tailored solutions for their patients.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.